Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?

Table 2 Treatment parameters and toxicities in phase III studies of postoperative radiotherapy for gastric cancer

Ref.	Group	Concurrent chemo	RT planning	RT dose (Gy)	RT target	Severe toxicity	Completed planned treatment
SWOG/INT-0116[3]	CRT	5FU + LV	2D	45	Tumor bed, LN (Nos. 1-16)	G3+, 41%, G4+ 32%(GI, 33%)	64%(17 due to toxic effect)
ARTIST[6]	CT-CRT-CT	Capecitabine	2D or 3D	45	LN (Nos. 7-9 and 12-16)	Similar toxicity profile between the two groups (mostly well tolerated)	82% (5 due to toxic effect, but 1 during CRT)
NCC, South Korea[7]	CRT	5FU + LV	2D or 3D	45	Tumor bed, LN (Nos. 1-16)	G3+ Hema; 20% vs 25%, G3+ GI; 17% vs 11%	87% (2 due to toxic effect)
IMRT, China[8]	CRT	5FU + LV	IMRT	45	Tumor bed, LN (Nos. 1-16)	Similar toxicity profile between the two groups (mostly well tolerated)	91% (4 due to toxic effect)

RT: Radiotherapy; CRT: Chemo-radiotherapy; 5FU + LV: Fluorouracil and leucovorin; LN: Lymph node; GI: Gastrointestinal; Hema: Hematologic; IMRT: Intensity modulated radiotherapy.